Form 8-K · Current Report · Filed 2025-02-11
Shareholders Approve Key Amendments at Twist Bioscience Annual Meeting
At Twist Bioscience Corporation's 2025 Annual Meeting, shareholders approved several key amendments, including the amendment and restatement of the Company's 2018 Equity Incentive Plan to increase the number of shares reserved for awards by 3,700,000 shares, amendments to the Amended and Restated Certificate of Incorporation to increase the authorized shares by 100,000,000 and provide for officer exculpation, and the election of three new directors.
- Filer
- Twist Bioscience Corporation TWST · NASDAQ
- Filed
- Accession
- 0001104659-25-011543
- CIK
- 0001581280
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The amendments and elections were made effective upon the filing of the Certificate of Amendment with the Delaware Secretary of State on February 10, 2025.
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Amendments to Articles of Incorporation or Bylaws
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$48.63
Next session
-6.7%
Since filing
+219.9%
Latest close
$155.56
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from TWST reporting the same item, with the next session's move:
Exhibits (2)
About Twist Bioscience Corporation
Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.
Never miss another TWST filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.